http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-587438-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c91c76b94cf2d18ea0309aa35a119bb0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-81 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
| filingDate | 2008-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4af0a51923ed0336c576d77861a51850 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_798ad0c3a272c4a290f60d4ca936c2a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8421e95c57ad9ebf8d93dbc44780a1a |
| publicationDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-587438-A |
| titleOfInvention | Optimized adhesin fragments comprising mutated afa/dra adhesions and corresponding nanoparticles |
| abstract | Disclosed is an adhesin comprising an amino acid sequence selected from the group consisting of the following sequences a. DraE group (SEQ ID No.3) b. DraE/AfaE-III (SEQ ID No.4) c. DraE (SEQ ID No.1) wherein said adhesin has one or more of the following mutations and may be deleted N-terminally by up to 18 amino acids: T7 (N, F, C, S, V, R, A, I, L, V); E17 (S, P, K, G, D, R, N, H, Q); R22 (T, A, S, N, K); D25 (S, G, N, A, T, K, R, H, Q, M); T27 (K, R, L, V, Y, P, N, Q); V28 (W, F); A29 (K, R, S, E, Q, F, G, L, H, P, N, T, W); T31 (G, D, S, N); Q34 (D, G, S, N, L, V, T, A); D37N; A38 (S, T, L); A39 (Q, S, D, M, G, F); 141 (V); Q47 (T, N, C, S, G, A, P); D52 (G, N, S, C, P, Q, Y, H, K, R, T); N84 (D, S, H); R86V; T88 (M, L); T95 (L, M, Y, F, C, W, Q, N, E, S, I, H); F100 (Y, V); V105 (S, A, T, R, M, V, P, N, E, Q, G, K, H); I111 (C, V, H, Y, T, M, F) I114 (V, L, A, C); Y115 (T, W, E, V); V116 (A, S, L); G118 (P, S); provided that when said adhesion contains a T88M and/or a N77K mutation, the adhesin comprises at least one further mutation selected from the above list. Also disclosed is a nanoparticle conjugated to the said adhesion. Further discloses is the use of the said adhesion or nanoparticle in the preparation of a contrast agent for medical use. |
| priorityDate | 2008-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 334.